Novo Nordisk's Application for Higher Wegovy Dose
Recently, Novo Nordisk A/S submitted an application to the European Medicines Agency (EMA) to gain approval for a higher dose of its obesity treatment, Wegovy (subcutaneous semaglutide 7.2 mg).
Clinical Trials Supporting the Application
This application is supported by clinical data gathered from the STEP UP and STEP UP T2D trials. These studies evaluate the effectiveness and safety of semaglutide 7.2 mg in adults suffering from obesity, as well as those with both obesity and type 2 diabetes.
Results from The STEP UP Trial
In the STEP UP trial, participants using the higher dose of Wegovy experienced an impressive average weight loss of 21%. Remarkably, around one-third of participants lost 25% or more of their body weight compared to those who received a placebo.
Safety Profile of Semaglutide 7.2 mg
Clinical data has indicated that semaglutide 7.2 mg presents a well-tolerated safety profile, similar to that of semaglutide 2.4 mg and previous trials conducted by Novo Nordisk concerning semaglutide.
Potential Risks Identified
Yet, some data point to a slightly increased risk of specific conditions among those taking semaglutide compared to the placebo group. The EMA's safety committee, PRAC, recently concluded its evaluation of medicines containing semaglutide, prompted by concerns regarding the risk of non-arteritic anterior ischemic optic neuropathy (NAION), which could potentially lead to vision loss.
NAION Evaluation Findings
After reviewing comprehensive data on NAION associated with semaglutide—including both clinical trials and post-marketing surveillance—the committee determined that NAION is a rare side effect of the medication, affecting roughly one out of every ten thousand users.
Wegovy and Market Competition
To strengthen its market position, Novo Nordisk introduced Wegovy (semaglutide) in India to compete with Eli Lilly and Co. (LLY). Currently, Wegovy is available in varying doses, including 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg. The initial three doses are priced at 4,336 rupees ($50.7), while the overall monthly cost stands at 17,345 rupees ($201.4), making it competitive with Eli Lilly's product, Mounjaro.
Lilly’s Growing Market Presence
While Wegovy marked a significant advancement in the treatment of obesity—resulting in net profits of $46 billion for Novo Nordisk since its U.S. approval in mid-2021—the company has encountered challenges, particularly with Eli Lilly’s Zepbound, which has outperformed Wegovy in terms of new weekly prescriptions this year.
Recent Stock Performance
As of the latest report on Tuesday, NVO stock was up 1.43%, trading at $70.32, indicating a positive trend amidst fierce competition in the weight loss drug market.
Frequently Asked Questions
What is Novo Nordisk's latest application about?
Novo Nordisk has submitted a request for EMA approval for a higher dose of Wegovy, a medication for obesity treatment.
What were the results of the STEP UP trial?
The STEP UP trial revealed participants lost an average of 21% of their body weight, with some losing over 25%.
Is the higher dose of semaglutide safe?
Yes, clinical data suggests the safety profile of semaglutide 7.2 mg is well tolerated.
What risks are associated with semaglutide?
There is a slightly elevated risk of developing NAION, though it is considered very rare.
How does Wegovy compare with Mounjaro?
Wegovy is priced competitively against Eli Lilly's Mounjaro, and both medications aim to address obesity effectively.
